Literatuurlijst

 

[1] Allen A, Hollander E. Diagnosis and treatment of obsessive-compulsive disorder. Primary Psychiatry. 2005;12:34-42.

 

[2] Jabben N, Arts B. Bipolaire stoornis [Internet]. 1st ed. Amsterdam: Hogrefe; 2011 [geciteerd op 7 April 2016]. Te verkrijgen via: https://www.boompsychologie.nl/documenten/hogrefe/41_jabben_arts_-_bipolaire_stoornis.pdf

 

[3] Diagnostic criteria for Manic Episode | BehaveNet [Internet]. Behavenet.com. 1994 [geciteerd op 7 April 2016]. Te verkrijgen via: http://behavenet.com/node/21571

 

[4] Amerio A, Tonna M, Odone A, Stubbs B, Ghaemi S. Course of illness in comorbid bipolar disorder and obsessive–compulsive disorder patients. Asian Journal of Psychiatry. 2016;20:12-14.

 

[5] Obsessieve-compulsieve stoornis (OCS) [Internet]. Brainclinics.com. 2016 [geciteerd op 6 April 2016]. Te verkrijgen via: http://www.brainclinics.com/obsessieve-compulsieve-stoornis-ocs

 

[6] Nissen J, Skarphedinsson G, Weidle B, Torp N, Lenhard F, Dahl K et al. Familial occurrence of tic disorder, anxiety and depression is associated with the clinical presentation of obsessive compulsive disorder (OCD) in children and adolescents. Journal of Obsessive-Compulsive and Related Disorders. 2016;9:59-65.

 

[7] Obsessieve-compulsieve stoornis [Internet]. Nl.wikipedia.org. 2016 [geciteerd op 6 April 2016]. Te verkrijgen via: https://nl.wikipedia.org/wiki/Obsessieve-compulsieve_stoornis

 

[8] Ruscio A, Stein D, Chiu W, Kessler R. The epidemiology of obsessive-compulsive disorder in the National Comorbidity Survey Replication. Molecular Psychiatry. 2008;15(1):53-63.

 

[9] Fontenelle L, Mendlowicz M, Versiani M. The descriptive epidemiology of obsessive–compulsive disorder. Progress in Neuro-Psychopharmacology and Biological Psychiatry. 2006;30(3):327-337.

 

[10] Kessler R, Berglund P, Demler O, Jin R, Merikangas K, Walters E. Lifetime Prevalence and Age-of-Onset Distributions of DSM-IV Disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry. 2005;62(6):593.

 

[11] Emmelkamp P, Ehring T. The Wiley handbook of anxiety disorders. Chichester, West Sussex, UK: Wiley Blackwell; 2014.

 

[12] Wittchen H, Jacobi F. Size and burden of mental disorders in Europe—a critical review and appraisal of 27 studies. European Neuropsychopharmacology. 2005;15(4):357-376.

 

[13] Megen van, H.J.G.M, Balkom, A.J.L.M. Leerboek psychiatrie; Hoofdstuk 12.2 Obsessieve-compulsieve stoornis. Utrecht, de Tijdstroom; 2005.

 

[14] Hollander E, Greenwald S, Neville D, Johnson J, Hornig C, Weissman M. Uncomplicated and comorbid obsessive-compulsive disorder in an epidemiologic sample. Depression and Anxiety. 1996;4(3):111-119. 

 

[15] Nestadt G, Grados M, Samuels J. Genetics of Obsessive-Compulsive Disorder. Psychiatric Clinics of North America. 2010;33(1):141-158. 

 

[16] Viswanath B, Narayanaswamy J, Cherian A, Reddy Y, Math S. Is Familial Obsessive-Compulsive Disorder Different from Sporadic Obsessive-Compulsive Disorder A Comparison of Clinical Characteristics, Comorbidity and Treatment Response. Psychopathology. 2011;44(2):83-89.

 

[17] Pauls D, Abramovitch A, Rauch S, Geller D. Obsessive–compulsive disorder: an integrative genetic and neurobiological perspective. Nature Reviews Neuroscience. 2014;15(6):410-424.

 

[18] Gonda X, Jekkel E, Varga A, Miklósi M, Forintos D. [Advantage of obsessive-compulsive symptoms from the aspect of individual selection and group selection: an evolutionary psychological approach to obsessive-compulsive disorder]. Neuropsychopharmacologica Hungarica. 2008;10(4):225-232. 

 

[19] Ahmari S. Using mice to model Obsessive Compulsive Disorder: From genes to circuits. Neuroscience. 2016;321:121-137.

 

[20] Harsányi A, Csigó K, Némenth A. [New approach to obsessive-compulsive disorder: dopaminergic theories]. Psychiatr Hung. 2007;22(4):248-258. 

 

[21] Aouizerate B, Rotgé J, Bioulac B, Tignol J. [Present contribution of neurosciences to a new clinical reading of obsessive-compulsive disorder]. Encephale. 2007;33(2):203-210. 

 

[22] Stahl S. Stahl's essential psychopharmacology. Cambridge: Cambridge University Press; 2013.

 

[23] Stahl S, Muntner N. Mood disorders and antidepressants. 

 

[24] Grünblatt E, Hauser T, Walitza S. Imaging genetics in obsessive-compulsive disorder: Linking genetic variations to alterations in neuroimaging. Progress in Neurobiology. 2014;121:114-124.

 

[25] El Mansari M, Blier P. Mechanisms of action of current and potential pharmacotherapies of obsessive-compulsive disorder. Progress in Neuro-Psychopharmacology and Biological Psychiatry. 2006;30(3):362-373.

 

[26] Vinkers D, van der Wee N. A. Koninklijke Academie voor Geneeskunde van België. Diepe hersenstimulatie bij obsessieve compulsieve stoornis (OCD-patiënten: dwangneurose). Tijdschrift voor Geneeskunde. 2003;59(10):699-700.

 

[27] Erbay L, Ozcan O, Kartalci Ş, Yüksel T, Özlem Kütük M. No evidence of androgenic neurosteroid involvement in pediatric OCD. Journal of Obsessive-Compulsive and Related Disorders. 2015;6:97-100.

 

[28] Adam Y, Meinlschmidt G, Gloster AT, et al. Obsessive–compulsive disorder in the community: 12-month prevalence, comorbidity and impairment. Psychiatr Epidemiol 2012;47:339-49

 

[29] Abramowitz JS, Franklin ME, Zoellner LA, DiBernardo CL. Treatment compliance and outcome in obsessive-compulsive disorder. Behav Modif. 2002;26:447-63.

 

[30] van Oppen P, van Balkom A, de Haan E, van Dyck R. Cognitive Therapy and Exposure in Vivo Alone and in Combination With Fluvoxamine in Obsessive-Compulsive Disorder. J Clin Psychiatry. 2005;66(11):1415-1422.

 

[31] Kenemans L. Psychofarmacologie. Den Haag: Boom Lemma uitgevers; 2011. 

 

[32] FarmacotherapeutischKompas [Internet]. Farmacotherapeutischkompas.nl. [geciteerd op 7 April 2016]. Te verkrijgen via: http://www.farmacotherapeutischkompas.nl/

 

[33] van Balkom A, van Vliet I, Emmelkamp P, Bockting C, Spijker J, Hermens M et al. [Internet]. 3rd ed. 2013 [geciteerd op  6 April 2016]. : 6. [Internet]. Te verkrijgen via: https://www.nhg.org/sites/default/files/content/nhg_org/uploads/multidisciplinaire_richtlijn_angststoornissen_3e_revisie_2013.pdf

 

[34] FarmacotherapeutischKompas [Internet]. Farmacotherapeutischkompas.nl. 2016 [geciteerd op 6 April 2016]. Te verkrijgen via: http://www.farmacotherapeutischkompas.nl/bladeren-volgens-boek/inleidingen/inl-anxiolytica

 

[35] Koran L, Hackett E, Rubin A, Wolkow R, Robinson D. Efficacy of Sertraline in the Long-Term Treatment of Obsessive-Compulsive Disorder. American Journal of Psychiatry. 2002;159(1):88-95.

 

[36] Nederlands Kenniscentrum Angst en Depressie [Internet]. 1st ed. 2016 [geciteerd op 6 April 2016]. A Te verkrijgen via:http://nedkad.nl/img/Atypische%20antipsychotica%20bij%20OCS.pdf

 

[37] Yale-Brown Obsessive Compulsive Scale [Internet]. Psychology Tools. 2016 [cited 27 April 2016]. Available from: https://psychology-tools.com/yale-brown-obsessive-compulsive-scale/ 

 

[38] van Grootheest D, van den Heuvel O, Cath D, van Oppen P, van Balkom A. Obsessieve-Compulsieve Stoornis. Nederlands Tijdschrift voor de Geneeskunde. 2008;152:2325-2329.

 

[39] Psychologen Praktijk Bosveld [Internet]. 1st ed. 2016 [geciteerd op  6 April 2016]. Te verkrijgen via:http://www.psychologenpraktijkbosveld.nl/documents/voorlichting/folder%20dwangstoornis.pdf

 

[40] Eddy K, Dutra L, Bradley R, Westen D. A multidimensional meta-analysis of psychotherapy and pharmacotherapy for obsessive-compulsive disorder. Clinical Psychology Review. 2004;24(8):1011-1030.

 

[41] Foa E, Liebowitz M, Kozak M, Davies S, Campeas R, Franklin M et al. Randomized, Placebo-Controlled Trial of Exposure and Ritual Prevention, Clomipramine, and Their Combination in the Treatment of Obsessive-Compulsive Disorder. FOC. 2007;5(3):368-380.

 

[42] https://www.hersenstichting.nl/alles-over-hersenen/hersenaandoeningen/onderzoekstechnieken-en-behandelingen/deep-brain-stimulation

 

[43] Lakhan S, Callaway E. Deep brain stimulation for obsessive-compulsive disorder and treatment-resistant depression: systematic review. BMC Research Notes. 2010;3(1):60.

 

[44] Jenike M. Cingulotomy for Refractory Obsessive Compulsive Disorder. Arch Gen Psychiatry. 1991;48(6):548.

 

[45] Lopes A, Greenberg B, Pereira C, Norén G, Miguel E. Notice of Retraction and Replacement. Lopes et al. Gamma ventral capsulotomy for obsessive-compulsive disorder: a randomized clinical trial. JAMA Psychiatry. 2014;71(9):1066-1076.

 

[46] Mindus P, Rasmussen S, Lindquist C. Neurosurgical treatment for refractory obsessive-compulsive disorder: implications for understanding frontal lobe function. Journal of Neuropsychiatry. 1994;6:467-477.

 

[47] Kupka R, Goossens P, van Bendegem M, Daemen P, Daggenvoorde T, Daniels M et al. Multidisciplinaire richtlijn bipolaire stoornissen [Internet]. 3rd ed. Utrecht: De Tijdstroom; 2015 [geciteerd op 7 April 2016]. Te verkrijgen via: http://www.nvvp.net/stream/richtlijn-bipolaire-stoornissen-2015

 

[48] http://www.tijdschriftvoorpsychiatrie.nl/assets/articles/articles_1329pdf.pdf

 

[49] Government U. Managing depressive symptoms in substance abuse clients during early recovery. [Place of publication not identified]: Books Llc; 2012.

 

[50] NIMH » Bipolar Disorder [Internet]. Nimh.nih.gov. 2016 [geciteerd op 7 April 2016]. Te verkrijgen via: https://www.nimh.nih.gov/health/topics/bipolar-disorder/index.shtml#part_145404

 

[51] http://renjedipweg.nl/informatie-depressies/depressie-en-schildklier/

 

[52] Bipolaire stoornis [Internet]. Farmacotherapeutischkompas.nl. [geciteerd op 7 April 2016]. Te verkrijgen via: http://www.farmacotherapeutischkompas.nl/bladeren-volgens-boek/inleidingen/inl-bipolaire-stoornis

 

[53] Kroon J, Wohlfarth T, Dieleman J, Sutterland A, Storosum J, Denys D et al. Incidence rates and risk factors of bipolar disorder in the general population: a population-based cohort study. Bipolar Disorders. 2013;15(3):306-313.

 

[54] Centorrino F, Hennen J, Mallya G, Egli S, Clark T, Baldessarini R. Clinical outcome in patients with bipolar I disorder, obsessive compulsive disorder or both. Human Psychopharmacology: Clinical and Experimental. 2006;21(3):189-193.

 

[55] Amerio A, Odone A, Marchesi C, Ghaemi S. Treatment of comorbid bipolar disorder and obsessive–compulsive disorder: A systematic review. Journal of Affective Disorders. 2014;166:258-263.

 

[56] Amerio A, Stubbs B, Odone A, Tonna M, Marchesi C, Ghaemi S. The prevalence and predictors of comorbid bipolar disorder and obsessive–compulsive disorder: A systematic review and meta-analysis. Journal of Affective Disorders. 2015;186:99-109.

 

[57] Tonna M, Amerio A, Odone A, Stubbs B, Ghaemi S. Comorbid bipolar disorder and obsessive-compulsive disorder: Which came first?. Australian & New Zealand Journal of Psychiatry. 2015;

 

[58] Daihui PE, JIANG K. Comorbid bipolar disorder and obsessive-compulsive disorder. Shanghai archives of psychiatry. 2015 Aug 25;27(4):246.

 

[59] Bressert S. The Causes of Bipolar Disorder (Manic Depression) [Internet]. Psych Central.com. 2016 [geciteerd op 7 April 2016]. Te verkrijgen via: http://psychcentral.com/lib/the-causes-of-bipolar-disorder-manic-depression/

 

[60] Kerner B. Genetics of bipolar disorder. TACG. 2014;:33.

 

[61] Enkel-nucleotide polymorfie [Internet]. Nl.wikipedia.org. 2015 [geciteerd op 7 April 2016]. Te verkrijgen via: https://nl.wikipedia.org/wiki/Enkel-nucleotide_polymorfie

 

[62] Bipolar disorder - Causes - NHS Choices [Internet]. Nhs.uk. 2014 [geciteerd op 7 April 2016]. Te verkrijgen via: http://www.nhs.uk/Conditions/Bipolar-disorder/Pages/Causes.aspx

 

[63] Manji H, Quiroz J, Payne J, Singh J, Lopes B, Viegas J et al. The underlying neurobiology of bipolar disorder. World Psychiatry. 2003;2(3):136-146.

 

[64] Köhnke M, Wiatr G, Kolb W, Köhnke A, Schick S, Lutz U et al. Plasma Homovanillic Acid: A Significant Association with Alcoholism is Independent of a Functional Polymorphism of the Human Catechol-O-Methyltransferase Gene.Neuropsychopharmacology.2002;.        

                                                                                                                          

[65] Yatham L, Goldstein J, Vieta E, Bowden C, Grunze H, Post R et al. Atypical antipsychotics in bipolar depression: potential mechanisms of action. J Clin Psychiatry. 2005;66 Suppl 5:40-48.

 

[66] 5-HIAA onderzoek in urine [Internet]. 1st ed. [geciteerd op 7 April 2016]. Te verkrijgen via: http://www.lab-west.nl/documenten%5CLW%205-HIAA%20urine%20onderzoek%20A5%20liggend.pdf

 

[67] Grunze H, Schlösser S, Amann B, Walden J. Anticonvulsant drugs in bipolar disorder. Dialogues Clin Neurosci. 1999;1(1):24-40.

 

[68] Shashidhara M, Sushma B, Viswanath B, Math S, Janardhan Reddy Y. Comorbid obsessive compulsive disorder in patients with bipolar-I disorder. Journal of Affective Disorders. 2015;174:367-371.

 

[69] Amerio A, Odone A, Liapis C, Ghaemi S. Diagnostic validity of comorbid bipolar disorder and obsessive-compulsive disorder: a systematic review. Acta Psychiatrica Scandinavica. 2014;129(5):343-358.

 

[70] Perugi G, Toni C, Frare F, Travierso M, Hantouche E, Akiskal H. Obsessive-Compulsive–Bipolar Comorbidity: a systematic exploration of clinical features and treatment outcome. The Journal of clinical psychiatry,. 2002;63(12), 1129-1134.

 

[71] Lithium [Internet]. Farmacotherapeutischkompas.nl. [geciteerd op 7 April 2016]. Te verkrijgen via: http://www.farmacotherapeutischkompas.nl/bladeren-volgens-boek/preparaatteksten/l/lithium

 

[72] Lithium [Internet]. Farmacotherapeutischkompas.nl. [geciteerd op 7 April 2016]. Te verkrijgen via: http://www.farmacotherapeutischkompas.nl/bladeren-volgens-boek/inleidingen/inl-lithium--inleidende-tekst

 

[73] Stahl S. Lithium [Internet]. Stahlonline.cambridge.org. 2008 [geciteerd op 7 April 2016]. Te verkrijgen via: http://stahlonline.cambridge.org/en_prescribers_drug.jsf?page=9780521136723v01c056_p187-190.html.therapeutics&name=Lithium&title=Therapeutics

 

[74] Malhi G, Tanious M, Das P, Coulston C, Berk M. Potential Mechanisms of Action of Lithium in Bipolar Disorder. CNS Drugs. 2013;27(2):135-153.

 

[75] Öngür D, Jensen J, Prescot A, Stork C, Lundy M, Cohen B et al. Abnormal Glutamatergic Neurotransmission and Neuronal-Glial Interactions in Acute Mania. Biological Psychiatry. 2008;64(8):718-726. 

 

[76] Anti-epileptica [Internet]. Farmacotherapeutischkompas.nl. [geciteerd op 7 April 2016]. Te verkrijgen via: http://www.farmacotherapeutischkompas.nl/bladeren-volgens-boek/inleidingen/inl-anti-epileptica

 

[77] Brietzke E, Scheinberg M, Lafer B. Therapeutic potential of interleukin-6 antagonism in bipolar disorder. Medical Hypotheses. 2011;76(1):21-23.

 

[78] Valproïnezuur [Internet]. Farmacotherapeutischkompas.nl. [geciteerd op 7 April 2016]. Te verkrijgen via: http://www.farmacotherapeutischkompas.nl/bladeren-volgens-boek/preparaatteksten/v/valproinezuur

 

[79] Carbamazepine [Internet]. Farmacotherapeutischkompas.nl. [geciteerd op 7 April 2016]. Te verkrijgen via: http://www.farmacotherapeutischkompas.nl/bladeren-volgens-boek/preparaatteksten/c/carbamazepine

 

[80] Lamotrigine [Internet]. Farmacotherapeutischkompas.nl. [geciteerd op 7 April 2016]. Te verkrijgen via: http://www.farmacotherapeutischkompas.nl/bladeren-volgens-boek/preparaatteksten/l/lamotrigine

 

[81] Ng F, Hallam K, Lucas N, Berk M. The role of lamotrigine in the management of bipolar disorder. Neuropsychiatr Dis Treat. 2007;3(4):463-747.

 

[82] Reynolds G. Receptor mechanisms of antipsychotic drug action in bipolar disorder - focus on asenapine. Therapeutic Advances in Psychopharmacology. 2011;1(6):197-204.

 

[83] Kelmendi B, Holsbach-Beltrame M, McIntosh A, Hilt L, George E, Kitchen R et al. Association of polymorphisms in HCN4 with mood disorders and obsessive compulsive disorder. Neuroscience Letters. 2011;496(3):195-199.

 

[84] Kelmendi B, Holsbach-Beltrame M, McIntosh A, Hilt L, George E, Kitchen R et al. Association of polymorphisms in HCN4 with mood disorders and obsessive compulsive disorder. Neuroscience Letters. 2011;496(3):195-199.

 

[85] Cannon D, Ichise M, Fromm S, Nugent A, Rollis D, Gandhi S et al. Serotonin transporter binding in major depressive disorder and bipolar disorder assessed using [11C]DASB and positron emission tomography. NeuroImage. 2006;31:T42.

 

[86] Pallanti S, Grassi G. Pharmacologic treatment of obsessive-compulsive disorder comorbidity. Expert Opinion on Pharmacotherapy. 2014;15(17):2543-2552.

 

[87] Amerio A, Odone A, Marchesi C, Ghaemi S. Treatment of comorbid bipolar disorder and obsessive–compulsive disorder: A systematic review. Journal of Affective Disorders. 2014;166:258-263.

 

[88] Fineberg N, Reghunandanan S, Brown A, Pampaloni I. Pharmacotherapy of obsessive-compulsive disorder: Evidence-based treatment and beyond. Australian & New Zealand Journal of Psychiatry. 2012;47(2):121-141. 

 

[89] Biernacka J, McElroy S, Crow S, Sharp A, Benitez J, Veldic M et al. Pharmacogenomics of antidepressant induced mania: A review and meta-analysis of the serotonin transporter gene (5HTTLPR) association. Journal of Affective Disorders. 2012;136(1-2):e21-e29.

 

[90] Raja M, Azzoni A. Clinical management of obsessive-compulsive-bipolar comorbidity: a case series. Bipolar Disorders. 2004;6(3):264-270.

 

[91] Amerio A, Odone A, Marchesi C, Ghaemi S. Do antidepressant-induced manic episodes in obsessive-compulsive disorder patients represent the clinical expression of an underlying bipolarity?. Australian & New Zealand Journal of Psychiatry. 2014;48(10):957-957.

 

[92] Tondo L, Vázquez G, Baldessarini R. Mania associated with antidepressant treatment: comprehensive meta-analytic review. Acta Psychiatrica Scandinavica. 2009;121(6):404-414.

 

[93] Malhi G, Masson M, Bellivier F. Teasing apart Bipolar III: The causes and consequences of a Treatment-Emergent Affective Switch (TEAS) into mania. Australian & New Zealand Journal of Psychiatry. 2015;49(10):866-868.

 

[94] van Enkhuizen J, Janowsky D, Olivier B, Minassian A, Perry W, Young J et al. The catecholaminergic–cholinergic balance hypothesis of bipolar disorder revisited. European Journal of Pharmacology. 2015;753:114-126.

 

[95] Young J, Dulcis D. Investigating the mechanism(s) underlying switching between states in bipolar disorder. European Journal of Pharmacology. 2015;759:151-162.

 

[96] Salvadore G, Quiroz J, Machado-Vieira R, Henter I, Manji H, Zarate C. The Neurobiology of the Switch Process in Bipolar Disorder. J Clin Psychiatry. 2010;71(11):1488-1501.

 

[97] Mundo E, Walker M, Cate T, Macciardi F, Kennedy J. The Role of Serotonin Transporter Protein Gene in Antidepressant-Induced Mania in Bipolar Disorder. Arch Gen Psychiatry. 2001;58(6):539.

 

[98] Porcelli S, Fabbri C, Serretti A. Meta-analysis of serotonin transporter gene promoter polymorphism (5-HTTLPR) association with antidepressant efficacy. European Neuropsychopharmacology. 2012;22(4):239-258.

 

[99] Frye M, McElroy S, Prieto M, Harper K, Walker D, Kung S et al. Clinical Risk Factors and Serotonin Transporter Gene Variants Associated With Antidepressant-Induced Mania. J Clin Psychiatry. 2015;:174-180.